Co-Diagnostics Announces New Vector Control Orders and Continued Progress Toward Regulatory Clearance for Coronavirus Test

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it has received new orders for its vector control tests and equipment from mosquito abatement districts following attendance at several vector control conferences. Recent conference appearances included a presentation at the 3rd International Conference on Zika Virus and Aedes Related Infections on February 13-16, 2020, in Washington, D.C., where Co-Diagnostics was well-received by the global audience. [ABSTRACT FROM PUBLISHER]